Close Menu

NEW YORK (GenomeWeb) — OpGen today priced a public offering of 9 million shares of its common stock at $.60 per share, giving the planned transaction a $5.4 million value.

The Gaithersburg, Maryland-based company said that it has also granted the underwriters of the offering a 45-day option to buy an additional 1.35 million shares to cover overallotments. Aegis Capital acted as the sole bookrunner for the offering, which is expected to close around March 28.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.